Tokyo, Japan – April 7, 2017 – REGiMMUNE Corporation announced the closing of a Series E financing on April 7th. The company raised 6 million US in this new round, which was led by SMBC Venture Capital Co., Ltd., the VC arm of Sumitomo Mitsui Banking Corporation(SMBC) and Japan Asia Investment Corporation (JAIC). Additional investors participating in this round are new investors Miyako Capital,Iyo-Gin Capital, Oita Venture Capital, Kyoritsu Captal,Hiroshima Venture Capital and several individual investors. Existing investors, and Mitsubishi UFJ Bank Capital also invested in this financing. Proceeds from this funding will be used clinical study in US.
REGiMMUNE successfully completed a Phase I/2a study of RGI-2001 for Graft versus Host Disease (GvHD) . Data from the Phase I/2a study showed no safety concerns up to the highest dose and some preliminary signs of efficacy were observed.
Kenzo Kosuda, President and Chief Executive Officer, said “We now have positive human clinical data that validates the usefulness of our immune-regulating technology platform. The financing announced today will allow us to start an addinotal clinical study to gain the more human data.”
About REGiMMUNE
REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The company’s proprietary platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. Using its reVax technology, REGiMMUNE is developing RGI-2001, which may be the first drug in the class of Treg-inducing agents.
The company is also applying its reVax technology to develop a range of pipeline products, including its RGI-1000 series for allergy and its RGI-3100 series for type 1 diabetes. Additionally REGiMMUNE is developing products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for IBD. The company is seeking pharmaceutical partnership opportunities for its products worldwide, exclusive of Japan. REGiMMUNE is headquartered in Tokyo, Japan and has a US operation in San Francisco, California. For more information, visit www.regimmune.com.